Novavax sviluppa anche [[Adiuvante (immunologia)|adiuvanti]] immunologici brevettati a base di [[saponina]] immuno-stimolantistimolante presso una consociata svedese interamente controllata, la Novavax AB. Uno di questi, Matrix-M,<ref name=bbc>{{cita web|lingua=en|url= https://www.bbc.com/future/article/20211201-what-will-the-next-generation-of-covid-19-vaccines-be-like|titolo= What will tomorrow's Covid-19 vaccines be like?}}</ref><ref>{{Cita pubblicazione|doi=10.1007/s12026-018-8991-x|titolo=Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice|anno=2018|cognome1=Magnusson|nome1=Sofia E.|cognome2=Altenburg|nome2=Arwen F.|cognome3=Bengtsson|nome3=Karin Lövgren|cognome4=Bosman|nome4=Fons|cognome5=De Vries|nome5=Rory D.|cognome6=Rimmelzwaan|nome6=Guus F.|cognome7=Stertman|nome7=Linda|rivista=Immunologic Research|volume=66|numero=2|pp=224–233|pmid=29594879|pmc=5899102}}</ref> è utilizzato nel vaccino di Novavax per il COVID-19, il Nuvaxovid.<ref>{{Cita web|titolo=Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate {{!}} Novavax Inc. - IR Site|url=https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-1-data-its-covid-19-vaccine|accesso=19 giugno 2021|sito=ir.novavax.com|lingua=en}}</ref><ref name=KHN>Sarah Jane Tribble and Rachana Pradhan. [https://khn.org/news/article/covid-vaccine-novavax-vaccination-effort-from-zero-to-not-quite-warp-speed/ Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed] Kaiser Health News, Kaiser Family Foundation, July 19, 2021.</ref>
